Retatrutide vs Tirzepatide: Which Is Right for You?
Both are incretin-mimetic peptides. Tirzepatide hits two receptors (GLP-1, GIP); retatrutide hits three (GLP-1, GIP, glucagon). That third receptor is what makes retatrutide so much stronger per milligram — and why it sits at the cutting edge of UK obesity research.
Mechanism
Tirzepatide — dual agonist. Slows gastric emptying, suppresses appetite, improves insulin sensitivity.
Retatrutide — triple agonist. All of the above plus glucagon-driven thermogenesis and lipolysis.
Published results
| Outcome | Tirzepatide | Retatrutide |
|---|---|---|
| Weight loss at 48 weeks (max dose) | ~21% | ~24% |
| Active receptors | 2 | 3 |
| Trial maturity | Phase 3 complete | Phase 2 complete; Phase 3 ongoing |
Side-effect profile
Both share the GI side-effect curve (nausea, slow gut) at higher doses. Retatrutide adds mild elevated heart rate in some subjects due to the glucagon component.
Cost in the UK
Retatrutide is currently more expensive per mg, but the per-effective-dose cost is similar because doses are lower.
Which should you pick?
- Want proven, predictable results? Tirzepatide.
- Want the strongest available effect and don't mind being on the research edge? Retatrutide.
Frequently asked questions
Is retatrutide approved by the MHRA?
No. Both are peptides only in the UK. Phase-3 trials are ongoing for retatrutide.
Can I run both together?
Stacking incretin mimetics is not supported by published data. Pick one.
Which has fewer side effects?
Tirzepatide, marginally — retatrutide's glucagon component adds mild cardiovascular changes.
Where can I buy both?
Both stocked at Next Day Pharma: tirzepatide and retatrutide.
This guide is provided for informational purposes by Next Day Pharma. All peptides supplied are FOR RECONSTITUTION. Always consult a qualified healthcare professional before use.